Chemistry:Olokizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| ATC code | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).
It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe whan.[2][3]
Olokizumab was approved for medical use in Russia. On May 21, 2020, the Russian Health Ministry approved brand name Artlegia (olokizumab).
Olokizumab (64 mg once) is used as emergence experimental cytokine storm COVID-19 complications treatment.[4]
In a 24-week, Phase 3, multicenter, placebo- and active-controlled trial, olokizumab (at a dose of 64 mg every 2 or 4 weeks) was superior to placebo and noninferior to adalimumab in producing a response at 12 weeks.[5]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103". WHO Drug Information. 2010. https://www.who.int/medicines/publications/druginformation/INN_PL103.pdf.
- ↑ Walsh, Nancy (6 August 2014). "RheumShorts: IL-6 and RA, Life and Death, Surgery in Lupus". http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/47086.
- ↑ "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Annals of the Rheumatic Diseases 73 (9): 1607–1615. September 2014. doi:10.1136/annrheumdis-2013-204760. PMID 24641941.
- ↑ "Russia's R-Pharm retools arthritis drug for COVID-19 patients in clinical trial". Reuters. 8 October 2020. https://www.reuters.com/article/us-health-coronavirus-russia-drug-idUSKBN26T2AN.
- ↑ "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis". The New England Journal of Medicine 387 (8): 715–726. August 2022. doi:10.1056/NEJMoa2201302. PMID 36001712.
External links
- "Olokizumab". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/olokizumab.
 |  |
